Malini M. Patel

Psychiatry
111 N County Farm Rd
Wheaton, IL 60187

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.

Journal: The Lancet. Respiratory medicine
Published: February 06, 2026

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

Journal: Cancer
Published: September 05, 2025

Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.

Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 21, 2024

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC.

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC.

Journal: JTO clinical and research reports
Published: February 28, 2024

In-situ hearing threshold estimation using Gaussian process classification.

In-situ hearing threshold estimation using Gaussian process classification.

Journal: Scientific reports
Published: March 20, 2023

Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.

Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.

Journal: Oncotarget
Published: December 06, 2022

A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.

A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.

Journal: Clinical lung cancer
Published: June 02, 2022

Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.

Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.

Journal: Oncotarget
Published: September 15, 2021

Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer.

Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer.

Journal: Journal of thoracic disease
Published: August 20, 2021

Relationships between prolonged physical and social isolation during the COVID-19 pandemic, reduced physical activity and disability in activities of daily living among people with advanced respiratory disease.

Relationships between prolonged physical and social isolation during the COVID-19 pandemic, reduced physical activity and disability in activities of daily living among people with advanced respiratory disease.

Journal: Chronic respiratory disease
Published: August 12, 2021

Combining radiation therapy and immunotherapy for lung cancers: a narrative review.

Combining radiation therapy and immunotherapy for lung cancers: a narrative review.

Journal: Shanghai chest
Published: February 01, 2021

Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer.

Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer.

Journal: Annals of palliative medicine
Published: January 22, 2021
Showing 1-12 of 19

Last Updated: 09/26/2026